Trending...
- Jacob Emrani's Annual "Supper Bowl" Expected To Donate Thousands Of Meals
- Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
- NASA / Glenn Research Center Collaboration to Help Meet Rising Demand for Space Energy Beaming Tech / CIGS PV Modules from Ascent Solar: NAS DAQ: ASTI
BEACHWOOD, Ohio, May 6, 2025 ~ Trailhead Biosystems Inc. has recently announced that it has secured $20 million in financing to further its advancements in human cell innovation. The biotechnology company, known for its expertise in differentiating induced pluripotent stem cells (iPSCs) into functional human cell types, aims to unlock new possibilities for research and cell therapy.
Led by MAK Capital with participation from additional investors, this investment comes at a crucial time for Trailhead as it looks to expand its personnel, manufacturing capabilities, and strategic partnerships. Through its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform, the company is able to optimize differentiation with exceptional accuracy, providing scalable solutions for both drug discovery and regenerative medicine.
The funding will also support Trailhead's rapidly growing portfolio of iPSC-derived cells for research applications. These cells are crucial in advancing preclinical drug discovery and disease modeling. Recently, the company introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs), a specialized cell type used in blood-brain barrier research. Upcoming product introductions include iPSC-derived pancreatic islets, hepatocytes, dopaminergic neurons, and hematopoietic progenitors.
More on Ohio Pen
In addition to its off-the-shelf offerings, Trailhead also offers custom cell differentiation services that allow scientists to refine existing models or develop novel cell types with precise biological fidelity. This dedication to providing highly specialized human cell models aligns with the FDA's shift towards using human-based lab models as alternatives to animal testing.
According to Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems, this investment will further advance their ability to differentiate iPSCs into precise human cell types for both drug discovery and therapeutic development. By optimizing scalable differentiation processes, the company aims to accelerate discovery and develop more predictive models while supporting the next generation of cell-based therapies.
Moreover, this funding will also strengthen Trailhead's ability to support therapeutic partners in driving innovation and scalability in cell-based therapies. Investments in infrastructure and personnel will enhance manufacturing capabilities, streamline production workflows, and deepen collaborations with leading industry partners in regenerative medicine.
With this latest investment, Trailhead Biosystems is well-positioned to continue its mission of advancing human cell innovation and driving breakthroughs in research and therapy.
Led by MAK Capital with participation from additional investors, this investment comes at a crucial time for Trailhead as it looks to expand its personnel, manufacturing capabilities, and strategic partnerships. Through its proprietary High-Dimensional Design of Experiments (HD-DoE®) platform, the company is able to optimize differentiation with exceptional accuracy, providing scalable solutions for both drug discovery and regenerative medicine.
The funding will also support Trailhead's rapidly growing portfolio of iPSC-derived cells for research applications. These cells are crucial in advancing preclinical drug discovery and disease modeling. Recently, the company introduced TrailBio® Vascular Leptomeningeal Cells (VLMCs), a specialized cell type used in blood-brain barrier research. Upcoming product introductions include iPSC-derived pancreatic islets, hepatocytes, dopaminergic neurons, and hematopoietic progenitors.
More on Ohio Pen
- VC Fast Pitch Is Coming to Maryland on March 26th
- Patent Bar Exam Candidates Achieve 30% Higher Pass Rates with Wysebridge's 2026 Platform
- Municipal Carbon Field Guide Launched by LandConnect -- New Revenue Streams for Cities Managing Vacant Land
- Hoy Law Wins Supreme Court Decision Establishing Federal Trucking Regulations as the Standard of Care in South Dakota
- Dr. Rashad Richey's Indisputable Shatters Records, Over 1 Billion YouTube Views, Top 1% Podcast, 3.2 Million Viewers Daily
In addition to its off-the-shelf offerings, Trailhead also offers custom cell differentiation services that allow scientists to refine existing models or develop novel cell types with precise biological fidelity. This dedication to providing highly specialized human cell models aligns with the FDA's shift towards using human-based lab models as alternatives to animal testing.
According to Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems, this investment will further advance their ability to differentiate iPSCs into precise human cell types for both drug discovery and therapeutic development. By optimizing scalable differentiation processes, the company aims to accelerate discovery and develop more predictive models while supporting the next generation of cell-based therapies.
Moreover, this funding will also strengthen Trailhead's ability to support therapeutic partners in driving innovation and scalability in cell-based therapies. Investments in infrastructure and personnel will enhance manufacturing capabilities, streamline production workflows, and deepen collaborations with leading industry partners in regenerative medicine.
With this latest investment, Trailhead Biosystems is well-positioned to continue its mission of advancing human cell innovation and driving breakthroughs in research and therapy.
0 Comments
Latest on Ohio Pen
- Iranian-Born Engineer Mohsen Bahmani Introduces Propeller-Less Propulsion for Urban Air Mobility
- Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
- RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
- Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
- 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
- OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
- New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
- Dr. Brendan Bauer and Jacqueline Graziani Join Mercy Health, Expanding Neurology Care on Cleveland's West Side
- Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
- Cincinnati Surgical Announces Partnership with 360 Wellness Education to Support Training
- The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing
- New Protection For Your Investment With Invizashield With Xpel PPF Servicing Anderson Twnsp, Ohio
- Joan Nissen promoted to Century Fasteners Corp. – General Manager, Aerospace & Government Sales
- Northwest Modern Fabrication Expands Manufacturing Capacity With 4,800 Sq. Ft. Addition
- NRE-HEALTH Radio Launches With a New Approach to Health Broadcasting
- From Coffee to Commutes: sMiles App Now Pays Bitcoin for Every Gift Card Purchase
- Finland's Health Authority Launches '2-4-2' Gambling Risk Limits Ahead of Expected Advertising Boom
- Dr. Billy B. Laun II Addresses Over 120 Dental Professionals at Annual Dental Meeting
- CCHR: Taxpayer Billions Wasted on Mental Health Research as Outcomes Deteriorate